<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617395</url>
  </required_header>
  <id_info>
    <org_study_id>120122</org_study_id>
    <secondary_id>12-N-0122</secondary_id>
    <nct_id>NCT01617395</nct_id>
  </id_info>
  <brief_title>Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility</brief_title>
  <official_title>Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Research shows that both genes and the environment influence a person s risk for getting&#xD;
      multiple sclerosis (MS). However, it is not possible to accurately predict who will develop&#xD;
      MS. Researchers want to study people with MS and their family members. They have developed a&#xD;
      Genetic and Environmental Risk Score for MS. This score combines information from a person's&#xD;
      medical history and genes. It also includes environmental factors that may be related to&#xD;
      developing MS. This study will test this risk score to see if it can help predict who will&#xD;
      develop MS.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To evaluate a score for genetic and environmental risk factors that may help predict&#xD;
      whether a person will develop MS.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Individuals at least 18 years of age who have MS.&#xD;
&#xD;
        -  Individuals between 18 to 50 years of age who are the parent, brother, sister, or child&#xD;
           of a person with MS.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  People with MS will allow researchers to look at their personal and medical data. These&#xD;
           data will have been collected in other MS-related studies.&#xD;
&#xD;
        -  Relatives of people with MS will fill out a questionnaire and give blood and saliva&#xD;
           samples. They will fill out the questionnaire again one year later.&#xD;
&#xD;
        -  Some relatives will have additional optional testing. These tests will include a&#xD;
           physical exam and imaging studies. There may also be other tests. These tests may be&#xD;
           repeated every 1 to 5 years for 20 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective. The overall objective of this study is to investigate the genetic, immune, and&#xD;
      neuroimaging profiles that may increase a person s risk of developing multiple sclerosis (MS)&#xD;
      in order to identify and validate predictive biomarkers in populations at risk for this&#xD;
      disorder.&#xD;
&#xD;
      Study population. There will be three study populations:&#xD;
&#xD;
        1. Individuals at risk for developing MS As part of the Genes and Environment in Multiple&#xD;
           Sclerosis (GEMS) study, we plan to recruit up to 1000 first-degree relatives of MS&#xD;
           patients. GEMS is a study aiming to recruit 5000 individuals that is being led by our&#xD;
           collaborators at Columbia University Medical Center. For the purposes of this study, a&#xD;
           first-degree relative may be a parent, sibling, or child between 18 and 50 years of age&#xD;
           but must not carry a diagnosis of MS. The first-degree relative must have the ability to&#xD;
           provide consent and be willing to participate in the study. Two potentially overlapping&#xD;
           subsets of these individuals will undergo detailed testing at the NIH:&#xD;
&#xD;
             1. The cross-sectional subcohort will consist of up to 150 participants with combined&#xD;
                genetic and environmental risk scores (GERS), defined in the protocol, in the&#xD;
                highest and lowest 20 percent of the entire study population. Selected participants&#xD;
                may be invited for follow-up studies based on data obtained at baseline if symptoms&#xD;
                develop.&#xD;
&#xD;
             2. The NINDS longitudinal subcohort will consist of up to 10 participants, ages 18 to&#xD;
                40,who express willingness to be followed for 20 years at the NIH, whose GERS falls&#xD;
                in the top 20 percent of the entire study population, and who have a first-degree&#xD;
                relative with MS who is participatipate&#xD;
&#xD;
        2. MS patients - We plan to recruit up to 1000 MS patients whose first-degree relatives are&#xD;
           enrolled this study. These participants either: (A) will be evaluated under other&#xD;
           Neuroimmunology Branch Clinic protocols and will not undergo separate evaluation under&#xD;
           this protocol; or (B) will send us medical records confirming their MS diagnosis via&#xD;
           mail/fax/secure email, without the requirement to participate in another NIH protocol.&#xD;
           The purpose of including this cohort in the current study is to allow access to their&#xD;
           clinical, biological, and imaging data for comparison with first-degree relatives, if&#xD;
           available, and to confirm that existing GEMS participants have a first-degree relative&#xD;
           diagnosed with MS.&#xD;
&#xD;
        3. Healthy volunteers - We plan to recruit up to 80 healthy volunteers, ages 18-50, who do&#xD;
           not have a known first-degree relative with MS. The purpose of including this cohort in&#xD;
           the current study is to allow quantification of the degree and extent of abnormalities,&#xD;
           including abnormalities of the blood-brain barrier, in individuals at risk for&#xD;
           developing MS. Without imaging data obtained from healthy volunteers, there is no way to&#xD;
           determine whether subtle clinical and neuroimaging findings in the at-risk cohort are&#xD;
           truly abnormal, or to correctly threshold and quantify the observed abnormalities.&#xD;
&#xD;
      Design. This is a prospective cohort natural-history study. All GEMS participants will&#xD;
      complete the following study procedures, which can be performed offsite: informed consent;&#xD;
      study questionnaire; saliva sample; and blood draw. The questionnaire will be repeated 1 year&#xD;
      after enrollment.&#xD;
&#xD;
      There will two additional substudies conducted at NIH: a cross-sectional substudy and a&#xD;
      longitudinal substudy. Participants in these substudies will be evaluated with clinical,&#xD;
      radiological, and laboratory procedures. Participants in the cross-sectional cohort will&#xD;
      undergo evaluation at the NIH at a single time point (with optional longitudinal follow up),&#xD;
      whereas participants in the longitudinal cohort will undergo evaluation at the NIH for 20&#xD;
      years. There will be an interim analysis 5 years after the 50th participant is recruited to&#xD;
      the longitudinal cohort, and the study of this cohort may be terminated if we have not&#xD;
      observed the development of MS-related radiological or laboratory abnormalities in any of the&#xD;
      participants. Participants with MS will provide informed consent to allow access to their own&#xD;
      research data, but the data themselves will be (or will have already been) collected under&#xD;
      other Neuroimmunology Clinic clinical protocols.&#xD;
&#xD;
      NIH is a unique site within the overall GEMS study, for the following reasons: (1) It is the&#xD;
      only site at which imaging is being performed, as part of the cross-sectional and&#xD;
      longitudinal substudies; (2) GEMS participants seen at NIH may undergo additional procedures&#xD;
      that are not part of the overall GEMS study; (3) Data from participants in the NIH substudy&#xD;
      will be directly linked to data from their own relatives with MS.&#xD;
&#xD;
      Outcome measures. For participants in the overall GEMS study, the primary outcome measure is&#xD;
      the GERS itself, as most participants in this cohort will not undergo further testing. For&#xD;
      participants in the cross-sectional cohort, which consists of individuals at highest and&#xD;
      lowest risk for MS, the primary outcome measure is the presence or absence of lesions on&#xD;
      T2-weighted brain MRI that meet the 2010 MRI criteria for dissemination in space - a finding&#xD;
      that, in this population, may well be related to MS. For participants in the longitudinal&#xD;
      cohort, the study endpoint is a clinical diagnosis of MS according to the same 2010 criteria.&#xD;
      Secondary outcome measures include: (1) The age at which participants develop MS-related&#xD;
      abnormalities on brain imaging studies, abnormalities on laboratory testing, and clinical&#xD;
      symptoms and signs; (2) The time lag between defined exposures (for example, infectious&#xD;
      mononucleosis) and the appearance of MS-related radiological, laboratory, and clinical&#xD;
      abnormalities; (3) The time lag between the appearance of asymptomatic radiological and&#xD;
      laboratory abnormalities and the onset of clinical symptoms; and (4) Additional exploratory&#xD;
      clinical, imaging, and biological data in the crosssectional that may suggest subclinical MS&#xD;
      disease activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2012</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>presence or absence of lesions on T2-weighted brain MRI</measure>
    <time_frame>ongoing</time_frame>
    <description>For participants in the cross-sectional cohort, which consists of individuals at highest and lowest risk for MS, the primary outcome measure is the presence or absence of lesions on T2-weighted brain MRI that meet the 2010 MRI criteria for dissemination in space</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GERS</measure>
    <time_frame>ongoing</time_frame>
    <description>For participants in the overall GEMS study, the primary outcome measure is the GERS itself, as most participants in this cohort will not undergo further testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>development of MS-like abnormalities on brain imaging studies, abnormalities on laboratory testing, and clinical symptoms and signs.</measure>
    <time_frame>ongoing</time_frame>
    <description>The age at which participants develop MS-related abnormalities on brain imaging studies, abnormalities on laboratory testing, andclinical symptoms and signs;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time lag between defined exposures</measure>
    <time_frame>ongoing</time_frame>
    <description>time lag between defined exposures (for example, infectious mononucleosis) and the appearance of MS-related radiological, laboratory, and clinical abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time lag between the appearance of asymptomatic radiological and laboratory abnormalities and the onset of clinical symptoms;</measure>
    <time_frame>ongoing</time_frame>
    <description>The time lag between the appearance of asymptomatic radiological and laboratory abnormalities and the onset of clinical symptoms;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exploratory clinical, imaging, biological data in the crosssectional</measure>
    <time_frame>ongoing</time_frame>
    <description>exploratory clinical, imaging, and biological data in the cross sectional that may suggest subclinical MS disease activity</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">181</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>GEMS cohort</arm_group_label>
    <description>Individuals at risk for developing MS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteer Cohort</arm_group_label>
    <description>Healthy volunteers, ages 18-50, who do not have a known first-degree relative with MS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MS Patients Cohort</arm_group_label>
    <description>MS patients whose first-degree relatives are enrolled in this study</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary clinical&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        GEMS cohort (target n equals 1000)&#xD;
&#xD;
          -  First-degree relative (parent, sibling, or child) of a self-reported MS patient.&#xD;
&#xD;
          -  Age 18-50, inclusive, at the time of enrollment into the overall GEMS study.&#xD;
&#xD;
          -  Willingness to be contacted regarding additional follow-up procedures.&#xD;
&#xD;
          -  Cross-sectional subcohort (target n equal 150):&#xD;
&#xD;
               -  Referred by Columbia University Medical Center as having a genetic and&#xD;
                  environmental risk score (GERS), defined in Section 4.1.1, in the top or bottom&#xD;
                  20% of the overall GEMS study.&#xD;
&#xD;
          -  NINDS Longitudinal subcohort (target n equal 100):&#xD;
&#xD;
               -  Ages 18-40, inclusive.&#xD;
&#xD;
               -  Referred by Columbia University Medical Center as having a GERS in the top 20% of&#xD;
                  the overall GEMS study.&#xD;
&#xD;
               -  Willing to undergo additional study procedures at the NIH for up to 20 years,&#xD;
                  with planned follow-up every year for participants between ages 18 and 25, every&#xD;
                  2 years for participants between ages 26 and 30, and every 5 years for&#xD;
                  participants between ages 31 and 40.&#xD;
&#xD;
               -  Relative enrolled in NIH study with confirmation of MS diagnosis.&#xD;
&#xD;
        MS patient cohort (target n=1000):&#xD;
&#xD;
          -  MS patients (NIH)&#xD;
&#xD;
               -  Co-enrolled in another Neuroimmunology Clinic natural history protocol.&#xD;
&#xD;
               -  Diagnosis confirmed at NIH.&#xD;
&#xD;
               -  Age 18 or older.&#xD;
&#xD;
          -  MS patient (non-NIH)&#xD;
&#xD;
               -  First-degree relative (parent, sibling, or child) of an existing GEMS&#xD;
                  participant.&#xD;
&#xD;
               -  Able and willing to send medical records associated with their MS diagnosis to&#xD;
                  NIH.&#xD;
&#xD;
          -  Healthy volunteer cohort (target n=80)&#xD;
&#xD;
               -  Age 18-50, inclusive.&#xD;
&#xD;
               -  No known first-degree relative (parent, sibling, or child) with MS.&#xD;
&#xD;
          -  All cohorts&#xD;
&#xD;
               -  Able to give informed consent.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        GEMS cohort&#xD;
&#xD;
        -Diagnosis of MS.&#xD;
&#xD;
        Cross-sectional and NINDS longitudinal subcohorts&#xD;
&#xD;
          -  Contraindications to MRI scanning.&#xD;
&#xD;
          -  Diagnosis of another central nervous system disease disease (CNS neoplasm, known&#xD;
             cerebrovascular disease, known CNS degenerative diseases, or known CNS inflammatory&#xD;
             diseases) at the time enrollment into the study.&#xD;
&#xD;
          -  MS cohort (both)&#xD;
&#xD;
             --None&#xD;
&#xD;
          -  Healthy volunteer cohort&#xD;
&#xD;
               -  Diagnosis of MS or another central nervous system (CNS neoplasm, cerebrovascular&#xD;
                  disease CNS degenerative diseases, or CNS inflammatory diseases) or a systemic&#xD;
                  disease that would interfere with the aims of this study.&#xD;
&#xD;
               -  Contraindications to MRI scanning.&#xD;
&#xD;
        Eligible NIH employees and staff may participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel S Reich, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health Clinical Center (CC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2012-N-0122.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hern√°n MA, Olek MJ, Hankinson SE, Hunter DJ. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 2001 Dec 26;286(24):3083-8.</citation>
    <PMID>11754673</PMID>
  </reference>
  <reference>
    <citation>Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006 Mar 23;354(12):1273-80. Review.</citation>
    <PMID>16554529</PMID>
  </reference>
  <reference>
    <citation>Chiappa KH. Use of evoked potentials for diagnosis of multiple sclerosis. Neurol Clin. 1988 Nov;6(4):861-80. Review.</citation>
    <PMID>3070342</PMID>
  </reference>
  <verification_date>September 21, 2021</verification_date>
  <study_first_submitted>June 8, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Magnetic Resonance Imaging (MRI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

